T. Rowe Price Investment Management
AZN icon

T. Rowe Price Investment Management’s AstraZeneca AZN Stock Holding History

T. Rowe Price Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-347
Closed -$64K – 674
2025
Q4 		$64K Sell
347
-224
-39% -$39.3K ﹤0.01% 662
2025
Q3 		$88K Buy
571
+114
+25% +$17.3K ﹤0.01% 661
2025
Q2 		$64K Buy
+457
New +$64K ﹤0.01% 663

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

T. Rowe Price Investment Management's AZN Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 347 shares — an estimated $64K sold.

T. Rowe Price Investment Management first reported a position in AZN in Q2 2025 and held it in 3 quarters. The position peaked at $88K in Q3 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 347 AstraZeneca shares in Q1 2026, an estimated $64K.
  • T. Rowe Price Investment Management first reported a position in AstraZeneca in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Investment Management's AstraZeneca position peaked at $88K in Q3 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.